{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:43:07Z","timestamp":1761057787975},"reference-count":132,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,1,1]]},"abstract":"<jats:p>Management of thrombophilia is an ever-changing field as new disorders are described and additional clinical experience accrues. This paper addresses three common management issues in the care of patients with thrombophilia. The first two topics are updates for common but perplexing hypercoagulable states and the last topic introduces a new option for optimal management of oral anticoagulant therapy. Dr. Jacob Rand updates and organizes the approach to patients with antiphospholipid syndrome. This syndrome is a common acquired thrombophilic state, but the diagnosis and treatment of patients remains a challenge. Dr. Rand outlines his diagnostic and treatment strategies based on the current understanding of this complicated syndrome. Dr. Barbara Konkle addresses the special concerns of managing women with thrombophilia. Hematologists are often asked to advise on the risks of hormonal therapy or pregnancy in a woman with a personal or family history of thrombosis or with an abnormal laboratory finding. Dr. Konkle reviews the available data on the risks of hormonal therapy and pregnancy in women with and without known underlying thrombophilic risk factors. In Section III, Dr. Gail Macik will discuss a new approach to warfarin management. Several instruments are now available for home prothrombin time (PT) monitoring. Self-testing and self management of warfarin are slowly emerging as reliable alternatives to traditional provider-based care and Dr. Macik reviews the instruments available and the results of studies that support this new management option.<\/jats:p>","DOI":"10.1182\/asheducation-2001.1.322","type":"journal-article","created":{"date-parts":[[2003,8,28]],"date-time":"2003-08-28T00:29:50Z","timestamp":1062030590000},"page":"322-338","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Thrombophilia: What's a Practitioner to Do?"],"prefix":"10.1182","volume":"2001","author":[{"given":"B. Gail","family":"Macik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob H.","family":"Rand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Konkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111619101017400_R1","unstructured":"Rand JH. The antiphospholipid syndrome. In Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams' Hematology. 6th ed. New York: McGraw-Hill; 2000:1715-1733."},{"key":"2019111619101017400_R2","doi-asserted-by":"crossref","unstructured":"Moore JE, Mohr CF. Biologically false positive serological tests for syphilis: type, incidence, and cause. J Am Med Assoc. 1952;150:467\u2013473.","DOI":"10.1001\/jama.1952.03680050033010"},{"key":"2019111619101017400_R3","unstructured":"Shapiro SS, Thiagarajan P. Lupus anticoagulants. Prog Hemost Thromb. 1982;6:263\u2013285."},{"key":"2019111619101017400_R4","doi-asserted-by":"crossref","unstructured":"Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309\u20131311.","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F"},{"key":"2019111619101017400_R5","doi-asserted-by":"crossref","unstructured":"Harris EN, Pierangeli SS. \u2018Equivocal\u2019 antiphospholipid syndrome. J Autoimmun. 2000;15:81\u201385.","DOI":"10.1006\/jaut.2000.0419"},{"key":"2019111619101017400_R6","doi-asserted-by":"crossref","unstructured":"Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism\u2014results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost. 1997;77:444\u2013451.","DOI":"10.1055\/s-0038-1655986"},{"key":"2019111619101017400_R7","doi-asserted-by":"crossref","unstructured":"Shapiro SS. The lupus anticoagulant\/antiphospholipid syndrome. Annu Rev Med. 1996;47:533\u2013553.","DOI":"10.1146\/annurev.med.47.1.533"},{"key":"2019111619101017400_R8","doi-asserted-by":"crossref","unstructured":"Triplett DA. Lupus anticoagulants\/antiphospholipid-protein antibodies: the great imposters. Lupus. 1996;5:431\u2013435.","DOI":"10.1177\/096120339600500519"},{"key":"2019111619101017400_R9","doi-asserted-by":"crossref","unstructured":"Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74:1185\u20131190.","DOI":"10.1055\/s-0038-1649901"},{"key":"2019111619101017400_R10","doi-asserted-by":"crossref","unstructured":"Jennings I, Kitchen S, Woods TA, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost. 1997;77:934\u2013937.","DOI":"10.1055\/s-0038-1656080"},{"key":"2019111619101017400_R11","doi-asserted-by":"crossref","unstructured":"Ginsberg JS, Wells PS, Brill Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;86:3685\u20133691.","DOI":"10.1182\/blood.V86.10.3685.bloodjournal86103685"},{"key":"2019111619101017400_R12","doi-asserted-by":"crossref","unstructured":"Wahl DG, Guillemin F, De-Maistre E, Perret GC, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998;7:15\u201322.","DOI":"10.1191\/096120398678919688"},{"key":"2019111619101017400_R13","doi-asserted-by":"crossref","unstructured":"Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood. 1986;68:869\u2013874.","DOI":"10.1182\/blood.V68.4.869.869"},{"key":"2019111619101017400_R14","doi-asserted-by":"crossref","unstructured":"Kitchens CS. Prolonged activated partial thromboplastin time of unknown etiology: a prospective study of 100 consecutive cases referred for consultation. Am J Hematol. 1988;27:38\u201345.","DOI":"10.1002\/ajh.2830270110"},{"key":"2019111619101017400_R15","doi-asserted-by":"crossref","unstructured":"Liu HW, Wong KL, Lin CK, Wong WS, Tse PW, Chan GT. The reappraisal of dilute tissue thromboplastin inhibition test in the diagnosis of lupus anticoagulant. Br J Haematol. 1989;72:229\u2013234.","DOI":"10.1111\/j.1365-2141.1989.tb07687.x"},{"key":"2019111619101017400_R16","doi-asserted-by":"crossref","unstructured":"Forastiero RR, Cerrato GS, Carreras LO. Evaluation of recently described tests for detection of the lupus anticoagulant. Thromb Haemost. 1994;72:728\u2013733.","DOI":"10.1055\/s-0038-1648949"},{"key":"2019111619101017400_R17","doi-asserted-by":"crossref","unstructured":"Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus. 1998;7:3\u20136.","DOI":"10.1191\/096120398678919624"},{"key":"2019111619101017400_R18","doi-asserted-by":"crossref","unstructured":"Silver RM, Porter TF, van Leeuween I, Jeng G, Scott JR, Branch DW. Anticardiolipin antibodies: clinical consequences of \u201clow titers\u201d. Obstet Gynecol. 1996; 87:494\u2013500.","DOI":"10.1016\/0029-7844(95)00497-1"},{"key":"2019111619101017400_R19","doi-asserted-by":"crossref","unstructured":"Selva-O'Callaghan A, Ordi-Ros J, Monegal-Ferran F, Martinez N, Cortes-Hernandez F, Vilardell-Tarres M. IgA anticardiolipin antibodies\u2014relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost. 1998;79:282\u2013285.","DOI":"10.1055\/s-0037-1614978"},{"key":"2019111619101017400_R20","unstructured":"Molina JF, Gutierrez US, Molina J, et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol. 1997;24:291\u2013296."},{"key":"2019111619101017400_R21","doi-asserted-by":"crossref","unstructured":"Tuhrim S, Rand JH, Wu XX, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke. 1999;30:1561\u20131565.","DOI":"10.1161\/01.STR.30.8.1561"},{"key":"2019111619101017400_R22","unstructured":"Colaco CB, Male DK. Anti-phospholipid antibodies in syphilis and a thrombotic subset of SLE: distinct profiles of epitope specificity. Clin Exp Immunol. 1985;59:449\u2013456."},{"key":"2019111619101017400_R23","doi-asserted-by":"crossref","unstructured":"Branch DW, Rote NS, Dostal DA, Scott JR. Association of lupus anticoagulant with antibody against phosphatidylserine. Clin Immunol Immunopathol. 1987;42:63\u201375.","DOI":"10.1016\/0090-1229(87)90173-5"},{"key":"2019111619101017400_R24","doi-asserted-by":"crossref","unstructured":"Harris EN. Antiphospholipid antibodies. Br J Haematol. 1990;74:1\u20139.","DOI":"10.1111\/j.1365-2141.1990.tb02530.x"},{"key":"2019111619101017400_R25","unstructured":"Merkel PA, Chang Y, Pierangeli SS, Harris EN, Polisson RP. Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with connective tissue diseases. J Rheumatol. 1999;26:591\u2013596."},{"key":"2019111619101017400_R26","unstructured":"Alarcon-Segovia D, Mestanza M, Cabiedes J, Cabral AR. The antiphospholipid\/cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to beta 2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. J Rheumatol. 1997;24:1545\u20131551."},{"key":"2019111619101017400_R27","doi-asserted-by":"crossref","unstructured":"Sanmarco M, Soler C, Christides C, et al. Prevalence and clinical significance of IgG isotype anti-beta 2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med. 1997;129:499\u2013506.","DOI":"10.1016\/S0022-2143(97)90004-4"},{"key":"2019111619101017400_R28","unstructured":"Tubach F, Hayem G, Marchand JL, et al. IgG anti-beta2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol. 2000;27:1437\u20131443."},{"key":"2019111619101017400_R29","doi-asserted-by":"crossref","unstructured":"Puurunen M, Vaarala O, Julkunen H, Aho K, Palosuo T. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol. 1996;80:16\u201322.","DOI":"10.1006\/clin.1996.0089"},{"key":"2019111619101017400_R30","doi-asserted-by":"crossref","unstructured":"Galli M. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome? J Autoimmun. 2000;15:101\u2013105.","DOI":"10.1006\/jaut.2000.0413"},{"key":"2019111619101017400_R31","doi-asserted-by":"crossref","unstructured":"Galli M, Barbui T. Prothrombin as cofactor for antiphospholipids. Lupus.1998;7 (Suppl 2):S37\u201340:S37\u2013S40","DOI":"10.1177\/096120339800700209"},{"key":"2019111619101017400_R32","doi-asserted-by":"crossref","unstructured":"McCrae KR. Antiphospholipid antibody associated thrombosis: a consensus for treatment? Lupus. 1996;5:560\u2013570.","DOI":"10.1177\/096120339600500602"},{"key":"2019111619101017400_R33","doi-asserted-by":"crossref","unstructured":"Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993\u2013997.","DOI":"10.1056\/NEJM199504133321504"},{"key":"2019111619101017400_R34","doi-asserted-by":"crossref","unstructured":"Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med. 1998;104:332\u2013338.","DOI":"10.1016\/S0002-9343(98)00060-6"},{"key":"2019111619101017400_R35","unstructured":"Urfer C, Pichler WJ, Helbling A. Antiphospholipid antibodies syndrome: follow-up of patients with a high antiphospholipid antibodies titer. Schweiz Med Wochenschr. 1996;126:2136\u20132140."},{"key":"2019111619101017400_R36","unstructured":"Finazzi G, Barbui T. Feasibility of a randomized clinical trial for the prevention of recurrent thrombosis in the antiphospholipid syndrome: the WAPS project. Provisional Steering Committee of the Warfarin in Antiphospholipid Syndrome (WAPS) Study. Ann Med Interne Paris. 1996;147 (Suppl 1):38\u201341."},{"key":"2019111619101017400_R37","doi-asserted-by":"crossref","unstructured":"Finazzi G. Ongoing randomized clinical trials for the treatment of thrombosis in the antiphospholipid syndrome. Hamostaseologie. 2001;21:77\u201381.","DOI":"10.1055\/s-0037-1619507"},{"key":"2019111619101017400_R38","doi-asserted-by":"crossref","unstructured":"Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [editorial]. Scand J Rheumatol1996;25:191\u2013193.","DOI":"10.3109\/03009749609069986"},{"key":"2019111619101017400_R39","doi-asserted-by":"crossref","unstructured":"Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine. 1998;77:195\u2013207.","DOI":"10.1097\/00005792-199805000-00005"},{"key":"2019111619101017400_R40","doi-asserted-by":"crossref","unstructured":"Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) [see comments]. Brit Med J. 1997;314:253\u2013257.","DOI":"10.1136\/bmj.314.7076.253"},{"key":"2019111619101017400_R41","doi-asserted-by":"crossref","unstructured":"Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174:1584\u20131589.","DOI":"10.1016\/S0002-9378(96)70610-5"},{"key":"2019111619101017400_R42","doi-asserted-by":"crossref","unstructured":"Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol. 1996;35:402\u2013407.","DOI":"10.1111\/j.1600-0897.1996.tb00501.x"},{"key":"2019111619101017400_R43","unstructured":"Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996;14:131\u2013136."},{"key":"2019111619101017400_R44","doi-asserted-by":"crossref","unstructured":"Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000;83:693\u2013697.","DOI":"10.1055\/s-0037-1613894"},{"key":"2019111619101017400_R45","doi-asserted-by":"crossref","unstructured":"Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999;81:668\u2013672.","DOI":"10.1055\/s-0037-1614550"},{"key":"2019111619101017400_R46","doi-asserted-by":"crossref","unstructured":"Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Am J Obstet Gynecol. 1997;176:1099\u20131100.","DOI":"10.1016\/S0002-9378(97)70409-5"},{"key":"2019111619101017400_R47","doi-asserted-by":"crossref","unstructured":"Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med. 1985;313:1322\u20131326.","DOI":"10.1056\/NEJM198511213132104"},{"key":"2019111619101017400_R48","doi-asserted-by":"crossref","unstructured":"Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 1997;337:148\u2013153.","DOI":"10.1056\/NEJM199707173370302"},{"key":"2019111619101017400_R49","doi-asserted-by":"crossref","unstructured":"Cowchock S. Treatment of antiphospholipid syndrome in pregnancy. Lupus.1998;7 (Suppl 2):S95\u20137:S95\u2013S97","DOI":"10.1177\/096120339800700221"},{"key":"2019111619101017400_R50","doi-asserted-by":"crossref","unstructured":"Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol. 2000;182:122\u2013127.","DOI":"10.1016\/S0002-9378(00)70500-X"},{"key":"2019111619101017400_R51","doi-asserted-by":"crossref","unstructured":"Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344:1527\u20131535.","DOI":"10.1056\/NEJM200105173442007"},{"key":"2019111619101017400_R52","doi-asserted-by":"crossref","unstructured":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: Results of international multicenter case-control study. Lancet. 1995;346:1575\u20131582.","DOI":"10.1016\/S0140-6736(95)91926-0"},{"key":"2019111619101017400_R53","doi-asserted-by":"crossref","unstructured":"Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet. 1995;346:1593\u20131596.","DOI":"10.1016\/S0140-6736(95)91929-5"},{"key":"2019111619101017400_R54","doi-asserted-by":"crossref","unstructured":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low dose oestrogen oral contraceptives on venous thromboembolic disease. Lancet1995;346:1582\u20131588.","DOI":"10.1016\/S0140-6736(95)91927-9"},{"key":"2019111619101017400_R55","doi-asserted-by":"crossref","unstructured":"Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Br Med J. 1996;312:83\u201388.","DOI":"10.1136\/bmj.312.7023.83"},{"key":"2019111619101017400_R56","doi-asserted-by":"crossref","unstructured":"Jick H, Jick Ss, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet. 1995;346:1589\u20131593.","DOI":"10.1016\/S0140-6736(95)91928-7"},{"key":"2019111619101017400_R57","doi-asserted-by":"crossref","unstructured":"O'Brien PA. The third generation oral contraceptive controversy: The evidence shows they are less safe than second generation pills. Br Med J. 1999;319:795\u2013796.","DOI":"10.1136\/bmj.319.7213.795"},{"key":"2019111619101017400_R58","doi-asserted-by":"crossref","unstructured":"Rosing J, Middeldorp S, Curvers J et al. Low-dose contraceptives and acquired resistance to activated protein C: A randomized cross-over study. Lancet. 1999;354:2036\u20132040.","DOI":"10.1016\/S0140-6736(99)06092-4"},{"key":"2019111619101017400_R59","doi-asserted-by":"crossref","unstructured":"Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KW, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: From epidemiologic controversy to insight in coagulation. Am J Obstet Gynecol. 1997;174:887\u2013891.","DOI":"10.1016\/S0002-9378(97)70289-8"},{"key":"2019111619101017400_R60","doi-asserted-by":"crossref","unstructured":"Rosing J, Tans G, Nicolaes GAF, et al. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 1997;97:233\u2013238.","DOI":"10.1046\/j.1365-2141.1997.192707.x"},{"key":"2019111619101017400_R61","doi-asserted-by":"crossref","unstructured":"Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453\u20131457.","DOI":"10.1016\/S0140-6736(94)90286-0"},{"key":"2019111619101017400_R62","doi-asserted-by":"crossref","unstructured":"Martinelli I, Taioli E, Bucciarelli P, Akhavean S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep venous thrombosis. Arterioscler Thromb Vasc Biol. 1999;19:700\u2013703.","DOI":"10.1161\/01.ATV.19.3.700"},{"key":"2019111619101017400_R63","doi-asserted-by":"crossref","unstructured":"Girolami A, Simioni P, Girolami B, Zanardi S. The role of drugs, particularly oral contraceptives, in triggering thrombosis in congenital defects of coagulation inhibitors: a study of six patients. Blood Coag Fibrinol. 1991;2:673\u2013678.","DOI":"10.1097\/00001721-199110000-00015"},{"key":"2019111619101017400_R64","doi-asserted-by":"crossref","unstructured":"Simioni P, Sanson B-J, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999;81:198\u2013202.","DOI":"10.1055\/s-0037-1614442"},{"key":"2019111619101017400_R65","doi-asserted-by":"crossref","unstructured":"Pabinger I, Schneider B, and the GTH Study Group on Natural Inhibitors. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost. 1994;71:548\u2013552.","DOI":"10.1055\/s-0038-1642480"},{"key":"2019111619101017400_R66","doi-asserted-by":"crossref","unstructured":"O'Donnell J. Tuddenham EG. Manning R. Kemball-Cook G. Johnson D. Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost. 1997;77:825\u2013828.","DOI":"10.1055\/s-0038-1656061"},{"key":"2019111619101017400_R67","doi-asserted-by":"crossref","unstructured":"Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152\u2013155.","DOI":"10.1016\/S0140-6736(95)90166-3"},{"key":"2019111619101017400_R68","doi-asserted-by":"crossref","unstructured":"O'Donnell J. Mumford AD. Manning RA. Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost. 2000;83:10\u201313.","DOI":"10.1055\/s-0037-1613748"},{"key":"2019111619101017400_R69","doi-asserted-by":"crossref","unstructured":"Kraaijenhagen RA, in\u2019t Anker PS, Koopman MMW, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000;83:5\u20139.","DOI":"10.1055\/s-0037-1613747"},{"key":"2019111619101017400_R70","doi-asserted-by":"crossref","unstructured":"Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR, Vandenbroucke. Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost. 1999;82:1024\u20131027.","DOI":"10.1055\/s-0037-1614323"},{"key":"2019111619101017400_R71","doi-asserted-by":"crossref","unstructured":"Martinelli I, Sacchi E, Landi G, Taioli E. Duca F. Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998; 338 :1793\u20131797.","DOI":"10.1056\/NEJM199806183382502"},{"key":"2019111619101017400_R72","doi-asserted-by":"crossref","unstructured":"Bloemenkamp KWM, Rosendaal FR, Kelmerhost FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000;160 :49\u201352.","DOI":"10.1001\/archinte.160.1.49"},{"key":"2019111619101017400_R73","doi-asserted-by":"crossref","unstructured":"Vasilakis C, Jick SS, Jick H. The risk of venous thrombembolism in users of postcoital contraceptive pills. Contraception. 1999;59:79\u201383.","DOI":"10.1016\/S0010-7824(99)00011-6"},{"key":"2019111619101017400_R74","doi-asserted-by":"crossref","unstructured":"Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet. 1999;354:1610\u20131611.","DOI":"10.1016\/S0140-6736(99)04394-9"},{"key":"2019111619101017400_R75","doi-asserted-by":"crossref","unstructured":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception. 1998;57:315\u2013324.","DOI":"10.1016\/S0010-7824(98)00041-9"},{"key":"2019111619101017400_R76","doi-asserted-by":"crossref","unstructured":"Nilsson CG. Two-year experience with two levonorgestrel IUDs and one copper releasing IUD: a randomized comparative performance study. Fertil Steril. 1983;39:187\u2013192.","DOI":"10.1016\/S0015-0282(16)46817-2"},{"key":"2019111619101017400_R77","doi-asserted-by":"crossref","unstructured":"Daly E, Vessey MP, Hawkins MW, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996; 348:977\u2013980.","DOI":"10.1016\/S0140-6736(96)07113-9"},{"key":"2019111619101017400_R78","doi-asserted-by":"crossref","unstructured":"Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens. Lancet. 1996; 348:981\u2013983.","DOI":"10.1016\/S0140-6736(96)07114-0"},{"key":"2019111619101017400_R79","doi-asserted-by":"crossref","unstructured":"Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996; 348:983\u2013987.","DOI":"10.1016\/S0140-6736(96)07308-4"},{"key":"2019111619101017400_R80","doi-asserted-by":"crossref","unstructured":"Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280:605\u2013613.","DOI":"10.1001\/jama.280.7.605"},{"key":"2019111619101017400_R81","doi-asserted-by":"crossref","unstructured":"Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb Haemost. 2000;83:530\u2013535.","DOI":"10.1055\/s-0037-1613857"},{"key":"2019111619101017400_R82","doi-asserted-by":"crossref","unstructured":"Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-positive tumors. J Natl Cancer Inst. 1996;88:1529\u20131542.","DOI":"10.1093\/jnci\/88.21.1529"},{"key":"2019111619101017400_R83","doi-asserted-by":"crossref","unstructured":"Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol. 1998;45:608\u2013612.","DOI":"10.1046\/j.1365-2125.1998.00733.x"},{"key":"2019111619101017400_R84","doi-asserted-by":"crossref","unstructured":"Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993\u20132000.","DOI":"10.1016\/S0140-6736(99)05036-9"},{"key":"2019111619101017400_R85","doi-asserted-by":"crossref","unstructured":"Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9:286\u2013294.","DOI":"10.1200\/JCO.1991.9.2.286"},{"key":"2019111619101017400_R86","doi-asserted-by":"crossref","unstructured":"Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404\u2013407.","DOI":"10.1056\/NEJM198802183180703"},{"key":"2019111619101017400_R87","doi-asserted-by":"crossref","unstructured":"Pritchard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol. 1996;14:2731\u20132737.","DOI":"10.1200\/JCO.1996.14.10.2731"},{"key":"2019111619101017400_R88","doi-asserted-by":"crossref","unstructured":"Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371\u20131388.","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"2019111619101017400_R89","doi-asserted-by":"crossref","unstructured":"Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637\u2013645.","DOI":"10.1001\/jama.282.7.637"},{"key":"2019111619101017400_R90","doi-asserted-by":"crossref","unstructured":"Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer. 1997;79:2024\u20132027.","DOI":"10.1002\/(SICI)1097-0142(19970515)79:10<2024::AID-CNCR25>3.0.CO;2-V"},{"key":"2019111619101017400_R91","doi-asserted-by":"crossref","unstructured":"Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 2000;342:374\u2013379.","DOI":"10.1056\/NEJM200002103420602"},{"key":"2019111619101017400_R92","doi-asserted-by":"crossref","unstructured":"McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;78:1183\u20131188.","DOI":"10.1055\/s-0038-1657712"},{"key":"2019111619101017400_R93","doi-asserted-by":"crossref","unstructured":"Ginsberg JS, Greer I, Hirsh J. Use of thrombotic agents during pregnancy. Chest. 2001;119 (Suppl 1):122S\u2013131S.","DOI":"10.1378\/chest.119.1_suppl.122S"},{"key":"2019111619101017400_R94","doi-asserted-by":"crossref","unstructured":"Walker ID. Management of thrombophilia in pregnancy. Blood Reviews. 1991;5:227\u2013233.","DOI":"10.1016\/0268-960X(91)90013-3"},{"key":"2019111619101017400_R95","doi-asserted-by":"crossref","unstructured":"Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet. 1999;353:1258\u20131265.","DOI":"10.1016\/S0140-6736(98)10265-9"},{"key":"2019111619101017400_R96","doi-asserted-by":"crossref","unstructured":"Brill-Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thrombosis. N Engl J Med. 2000;343:1439\u20131444.","DOI":"10.1056\/NEJM200011163432002"},{"key":"2019111619101017400_R97","doi-asserted-by":"crossref","unstructured":"Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost. 1999;82:6\u20139.","DOI":"10.1055\/s-0037-1614620"},{"key":"2019111619101017400_R98","doi-asserted-by":"crossref","unstructured":"Martinelli I, Taioli E, Cetin I, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med. 2000; 343:1015\u20131018.","DOI":"10.1056\/NEJM200010053431405"},{"key":"2019111619101017400_R99","doi-asserted-by":"crossref","unstructured":"Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340:9\u201313.","DOI":"10.1056\/NEJM199901073400102"},{"key":"2019111619101017400_R100","doi-asserted-by":"crossref","unstructured":"Meinardi JR, Middeldorp S, de Kam PJ, et al. Increased risk for fetal loss in carriers of the factor V Leiden. Ann Intern Med. 1999;130:736\u2013739.","DOI":"10.7326\/0003-4819-130-9-199905040-00013"},{"key":"2019111619101017400_R101","doi-asserted-by":"crossref","unstructured":"Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcomes in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000;83:693\u2013697.","DOI":"10.1055\/s-0037-1613894"},{"key":"2019111619101017400_R102","doi-asserted-by":"crossref","unstructured":"Vandenbroucke JP, van der Meer FJM, Helmerhost FM, Rosendaal FR. Factor V Leiden: Should we screen oral contraceptive users and pregnant women? Br Med J. 1996; 313: 1127\u20131130.","DOI":"10.1136\/bmj.313.7065.1127"},{"key":"2019111619101017400_R103","doi-asserted-by":"crossref","unstructured":"Hirsh J, Dalen JE, Anderson DR, et. al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114:445S\u2013469S.","DOI":"10.1378\/chest.114.5_Supplement.445S"},{"key":"2019111619101017400_R104","doi-asserted-by":"crossref","unstructured":"Murray ET, Fitzmaurice DA, Allan TF, Hobbs FD. A primary care evaluation of three near patient coagulometers. J Clin Pathol. 1999;52:842\u2013845.","DOI":"10.1136\/jcp.52.11.842"},{"key":"2019111619101017400_R105","doi-asserted-by":"crossref","unstructured":"Biasiolo A, Rampazzo P, Furnari O, et al. Comparison between routine laboratory prothrombin time measurements and fingerstick determinations using a near-patient testing device (ProTime). Thromb Res. 2000;97:495\u2013498.","DOI":"10.1016\/S0049-3848(99)00191-7"},{"key":"2019111619101017400_R106","doi-asserted-by":"crossref","unstructured":"Chapman DC, Stephens MA, Hamann GL, et al. Accuracy, clinical correlation, and patient acceptance of two handheld prothrombin time monitoring devices in the ambulatory setting. Ann Pharmacother. 1999;33:775\u2013780.","DOI":"10.1345\/aph.18317"},{"key":"2019111619101017400_R107","unstructured":"Macik BG. Designing a point-of-care program for coagulation testing. Arch Pathol Lab Med. 1995;119:929\u2013938."},{"key":"2019111619101017400_R108","unstructured":"Becker DM, Humphries JE, Walker FB, et al. Standardizing the prothrombin time: calibrating coagulation instruments as well as thromboplastin. Arch Patholo Lab Med. 1993;117:602\u2013605."},{"key":"2019111619101017400_R109","doi-asserted-by":"crossref","unstructured":"Gosselin R, Owings JT, White RH, et al. A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods. Thromb Haemost. 2000;83:698\u2013703.","DOI":"10.1055\/s-0037-1613895"},{"key":"2019111619101017400_R110","doi-asserted-by":"crossref","unstructured":"Kaatz SS, White RH, Hill J, et al. Accuracy of laboratory and portable monitor international normalized ratio determinations. Arch Intern Med. 1995;155:1861\u20131867.","DOI":"10.1001\/archinte.1995.00430170053006"},{"key":"2019111619101017400_R111","unstructured":"Vacas M, Fernandez MA, Martinez-Brotons F, et al. Comparative study of a portable prothrombin time monitor employing three different systems in oral anticoagulant units. Haemostasis. 2001; 31:18\u201325."},{"key":"2019111619101017400_R112","doi-asserted-by":"crossref","unstructured":"Tripodi A, Chantarangkul V, Mannucci P. Br J Haematolo. 2001; 113:847.","DOI":"10.1046\/j.1365-2141.2001.02753.x"},{"key":"2019111619101017400_R113","doi-asserted-by":"crossref","unstructured":"Jacobson AK. Patient self-management of oral anticoagulation therapy: An international update. J Thromb Thrombolysis. 1998;5:25\u201328.","DOI":"10.1023\/A:1013280702839"},{"key":"2019111619101017400_R114","doi-asserted-by":"crossref","unstructured":"Watzke HH, Forberg E, Svolba G, et al. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost. 2000;83:661\u2013665.","DOI":"10.1055\/s-0037-1613888"},{"key":"2019111619101017400_R115","doi-asserted-by":"crossref","unstructured":"Hasenkam JM, Knudsen L, Kimose HH, et al. Practicability of patient self-testing of oral anticoagulant therapy by the international normalized ratio (INR) using a portable whole blood monitor: A pilot investigation. Thromb Res. 1997;85:77\u201382.","DOI":"10.1016\/S0049-3848(96)00224-1"},{"key":"2019111619101017400_R116","unstructured":"Oral Anticoagulant Monitoring Study Group. Prothrombin measurement using a patient self-testing system. Am J Clin Pathol. 2001;115:280\u2013287."},{"key":"2019111619101017400_R117","doi-asserted-by":"crossref","unstructured":"Oral Anticoagulant Monitoring Study Group. Prothrombin measurement for professional and patient self-testing use: A multicenter clinical experience. Am J Clin Pathol. 2001;115:288\u2013296.","DOI":"10.1309\/KM0J-G5V9-KCAG-CLEE"},{"key":"2019111619101017400_R118","doi-asserted-by":"crossref","unstructured":"White RH, McCurdy SA, von Marensdorff H, et al. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study. Ann Intern Med. 1989;111:730\u2013737.","DOI":"10.7326\/0003-4819-111-9-730"},{"key":"2019111619101017400_R119","doi-asserted-by":"crossref","unstructured":"Anderson DR, Harrison L, Hirsh J. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy. Arch Intern Med. 1993;153:1441\u20131447.","DOI":"10.1001\/archinte.1993.00410120027004"},{"key":"2019111619101017400_R120","doi-asserted-by":"crossref","unstructured":"Lassen, JF, Brandslund I, Antonsen S. International normalized ratio for prothrombin times in patients taking oral anticoagulants: critical difference and probability of significant change in consecutive measurements. Clin Chem. 1995;41:444\u2013447.","DOI":"10.1093\/clinchem\/41.3.444"},{"key":"2019111619101017400_R121","doi-asserted-by":"crossref","unstructured":"Douketis JD, Lane A, Milne J, Ginsberg JS. Accuracy of a portable international normalization ratio monitor in outpatients receiving long-term oral anticoagulant therapy; comparison with a laboratory reference standard using clinically relevant criteria for agreement. Thromb Res. 1998;92:11\u201317.","DOI":"10.1016\/S0049-3848(98)00098-X"},{"key":"2019111619101017400_R122","doi-asserted-by":"crossref","unstructured":"Cosmi B, Palareti G, Moia M, et al. Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: a prospective multicenter study. Thromb Res. 2000;100:279\u2013286.","DOI":"10.1016\/S0049-3848(00)00323-6"},{"key":"2019111619101017400_R123","doi-asserted-by":"crossref","unstructured":"Ansell JE, Holden A Knapic N. Patient self-management of oral anticoagulation guided by capillary fingerstick whole blood prothrombin times. Arch Intern Med. 1989;149:2509\u20132511.","DOI":"10.1001\/archinte.1989.00390110085018"},{"key":"2019111619101017400_R124","doi-asserted-by":"crossref","unstructured":"Ansell JE, Patel N, Ostrovsky D, et al. Long-term patient self-management of oral anticoagulation. Arch Intern Med. 1995;155:2185\u20132189.","DOI":"10.1001\/archinte.1995.00430200066010"},{"key":"2019111619101017400_R125","doi-asserted-by":"crossref","unstructured":"Bernardo A. Experience with patient self-management of oral anticoagulation. J Thromb Thrombolysis. 1996;2:321\u2013325.","DOI":"10.1007\/BF01061920"},{"key":"2019111619101017400_R126","doi-asserted-by":"crossref","unstructured":"Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis. 1998;5:S19\u2013S24.","DOI":"10.1023\/A:1013228718768"},{"key":"2019111619101017400_R127","doi-asserted-by":"crossref","unstructured":"Marzinotto V, Monagle P, Chan A, et al. Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting. Pediatr Cardiol. 2000;21:347\u2013352.","DOI":"10.1007\/s002460010078"},{"key":"2019111619101017400_R128","doi-asserted-by":"crossref","unstructured":"Hasenkam JM, Kimose HH, Knudsen l, et al. Self-management of oral anticoagulant therapy after heart valve replacement. Eur J Cardio-Thorac Surg. 1997;11:935\u2013942.","DOI":"10.1016\/S1010-7940(97)01204-9"},{"key":"2019111619101017400_R129","doi-asserted-by":"crossref","unstructured":"Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;346:423\u2013428.","DOI":"10.1016\/S0140-6736(96)01109-9"},{"key":"2019111619101017400_R130","doi-asserted-by":"crossref","unstructured":"Ansell JE, Hughes R. Evolving models of warfarin management: Anticoagulation clinics, patient self-monitoring, and patient self management. Am Heart J. 1996;132:1095\u20131100.","DOI":"10.1016\/S0002-8703(96)90040-X"},{"key":"2019111619101017400_R131","doi-asserted-by":"crossref","unstructured":"Sawicki P. A structured teaching and self-management program for patients receiving oral anticoagulation. JAMA. 1999;281:145\u2013150.","DOI":"10.1001\/jama.281.2.145"},{"key":"2019111619101017400_R132","doi-asserted-by":"crossref","unstructured":"Kulinna W, Ney D, Wenzel T, et al. The effect of self-monitoring the INR on quality of anticoagulation and quality of life. Semin Thromb Hemost. 1999;25:123\u2013126.","DOI":"10.1055\/s-2007-996435"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2001\/1\/322\/18615\/Thrombophilia-Whats-a-Practitioner-to-Do","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2001\/1\/322\/18615\/Thrombophilia-Whats-a-Practitioner-to-Do","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T08:44:49Z","timestamp":1585125889000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2001\/1\/322\/18615\/Thrombophilia-Whats-a-Practitioner-to-Do"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,1]]},"references-count":132,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2001.1.322","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1,1]]}}}